

## Supplementary material

**Table S2: Antibiotic resistance rates based on *E. coli* isolates from PROGRESS study**

	<i>E. coli</i> episode from single UTI episode	<i>E. coli</i> episode from recurrent UTI group (recurrence)	All <i>E. coli</i> episode from both single and recurrent episode (overall)			
	N	Resistance %	N	Resistance	N	Resistance %
<b>Amoxicillin</b>	80	<b>37.5</b>	67	<b>43.3</b>	148	<b>39.9</b>
<b>Amoxicillin-clavulanic acid</b>	83	<b>36.1</b>	65	<b>40.0</b>	148	<b>37.8</b>
<b>Cefotaxime</b>	81	<b>4.9</b>	66	<b>4.5</b>	147	<b>4.8</b>
<b>Cefoxitin</b>	79	<b>21.5</b>	64	<b>17.2</b>	143	<b>19.6</b>
<b>Ceftazidime</b>	81	<b>2.5</b>	67	<b>4.5</b>	148	<b>3.4</b>
<b>Ceftriaxone</b>	81	<b>4.9</b>	67	<b>4.5</b>	148	<b>4.7</b>
<b>Ciprofloxacin</b>	81	<b>9.9</b>	67	<b>10.4</b>	148	<b>10.1</b>
<b>Cotrimoxazol</b>	81	<b>13.6</b>	67	<b>9.0</b>	148	<b>11.5</b>
<b>Fosfomycin</b>	81	<b>1.2</b>	67	<b>1.5</b>	148	<b>1.4</b>
<b>Gentamicin</b>	81	<b>3.7</b>	67	<b>0.0</b>	148	<b>2.0</b>
<b>Imipenem</b>	81	<b>0.0</b>	67	<b>0.0</b>	148	<b>0.0</b>
<b>Meropenem</b>	81	<b>0.0</b>	67	<b>0.0</b>	148	<b>0.0</b>
<b>Nitrofurantoin</b>	81	<b>6.2</b>	67	<b>1.5</b>	148	<b>4.1</b>
<b>Trimethoprim</b>	81	<b>19.8</b>	67	<b>9.0</b>	148	<b>14.9</b>
<b>Tobramycin</b>	79	<b>2.5</b>	64	<b>0.0</b>	143	<b>1.4</b>